MK, MDCCLXXV
alias:Mk1775, MK 1775
CAS:955365-80-7
MF:C27h32n8o2
MW:500.59538
Puritas:99.50%
Gradus:Pharmaceutical Grade
Aspectus:PULLUS
Notam NMAE:Hkylc
Standard:Usp
Stirpes:Missam stirpe
Repono copia ad 0-5 ℃
Stipare modos disposuerat mutavit Packing vias, 100% PRAETERSUS Custom
Delivery tempore in 18 horis post mercedem confirmata
Solutio:T / T, occidentalis unionem,Pecunia gram , BitCoin
Usage:MK, MDCCLXXV est inhibitor in LAPIS Kinase Wee1
Quid MK, MDCCLXXV?
MK, MDCCLXXV est inhibitor in LAPIS Kinase Wee1 (Ic50 = 5.2 NM).1 Hoc est ostensum est inhibere phosphorylation Cdc2 ad Tryosine, XV, Quod abrogat G2 DNA Damnum Checkpoint.1 in P53, deficiens tumores, qui confidunt solely in G2 LAPIS in DNA Damnum, MK, MDCCLXXV, In tandem cum DNA-Damaging Chemotherapeutica Agentibus, nuntiatum est ad inducere apoptosis in vitro et inhibitionis inhibitionis inhibitionis in vivo.
MK, MDCCLXXV curatio ducitur ad inhibition of Wee1 Kinase et reducitur inhibendo phosphorylation eius subiectum CDC2. MK, MDCCLXXV, Cum Dosed cum Gemcitabine, abrogata LAPIS comprehensionem promovere mitotic ingressum et facilitati tumore cell mors ut comparari potestate et gemcitabine tractata natalis tumores. MK, MDCCLXXV Monotherapy non inducere tumore regressuum. tamen, Et compositum de Gemcitabine cum MK, MDCCLXXV produci robusti anti-tumor actio et mirabiliter enhanced tumore procedere responsio (4.01 complicare) comparari gemcitabine curatio in P53, deficiens tumores. Tumor rursus incrementum curvas cogitavit post medicamento curatio tempus suadeant quod effectus ex coniunctim afficiens Lorem longior, diuturna quam Gemcitabine. Nemo ex agentibus produci tumor regressuum in P53, ferox genus Xenografts.
MK, MDCCLXXV inhibits wee1 Kinase in an ATP-competitive modo. Comparari wee1, MK, MDCCLXXV Displays 2- ad III-ovile minus potentia contra sic cum IC50 de 14 NM, 10-ovile minus potentiam contra septem aliis Kinases est >80% inhibitionis 1 μm, et >100-Complicare selectivity super humanum myt 1, Alius Kinase quod inhibits cyclin-dependens Kinase 1 (CDC2) per phosphorylation ad alternative site (Thr14).
Per abrogans DNA Damnum LAPIS per obsidionem Wee1 Activity in Widri cellulis portantes mutated P53, MK-MDCCLXXV curatio inhibits basalis phosphorylation Cdc2 at Tyr15 (CDC2Y15) Cum EC50 de 49 NM, et suppreses gemcitabine-, carboplatin- aut Cisplain-adductus phosphorylation Cdc2 et cellula exolvitur comprehensionem in dose-dependens modo, Cum EC50 de 82 NM et 81 NM, 180 NM et 163 NM, tum 159 NM et 160 NM, respective. MK, MDCCLXXV curatio solum ad 30-100 NM non habet significant Antiproliferative effectus in Wedpr et H1299 cellulis, Sed MK, MDCCLXXV ad 300 NM, Sufficit inhibere wee1 per >80%, Displays moderari sed significant antiproliferative effectus per 34.1% in Widro cellulis et 28.4% In H1299 cellulis.
